SCHEMBL16639345

SCHEMBL16639345

Cc1ccc(-c2ccc3oc4ccc5c(-c6ccc(C)cc6C)ccc6oc7ccc2c3c7-c4c65)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CDC25A P30304 1/20 0.39
CDC25C P30307 1/20 0.39
GAA P10253 2/20 0.34
ESR1 P03372 2/20 0.34
ESR2 Q92731 2/20 0.34
MAOB P27338 3/20 0.33
ADORA3 P0DMS8 2/20 0.33
MAOA P21397 1/20 0.33
ATM Q13315 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16639344 0.81 NPC1 (0.40) MAPTALDH1A1NPC1RAB9AHPGD
SCHEMBL10058056 0.79 MAOB (0.40) MAPTALDH1A1NPC1RAB9AHPGD
SCHEMBL16659630 0.77 TDP2 (0.34) ESR1ESR2
SCHEMBL10028108 0.77 CYP1A2 (0.46) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL21325563 0.75 MAPT (0.42) MAPTALDH1A1NPC1RAB9AHPGD
SCHEMBL24614347 0.73 ALDH1A1 (0.41) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL3043421 0.72 TDP1 (0.52) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL31547677 0.72 TDP1 (0.52) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL10028122 0.71 APP (0.32) ALDH1A1HPGDMAOBATM
SCHEMBL12777024 0.70 KDM4E (0.61) MAPTALDH1A1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150108447-A1 DIOXAANTHANTHRENE COMPOUND AND ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-23 US disclosed
US-20150108447-A1 DIOXAANTHANTHRENE COMPOUND AND ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-23 US disclosed
US-20150102308-A1 ORGANIC SEMICONDUCTOR LAYER, ELECTRONIC DEVICE, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-16 US disclosed
US-20150102308-A1 ORGANIC SEMICONDUCTOR LAYER, ELECTRONIC DEVICE, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE SONY CORPORATION (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150108447-A1 DIOXAANTHANTHRENE COMPOUND AND ELECTRONIC DEVICE CYP19A1, CYP1A1, DDT MAPT 3827/4885ALDH1A1 264/4885NPC1 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.